Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $9.8400 (-4.65%) ($9.4900 - $10.3300) on Tue. Mar. 31, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.87% (three month average) | RSI | 51 | Latest Price | $9.8400(-4.65%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.7% a day on average for past five trading days. | Weekly Trend | TGTX advances 11.5% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(58%) IBB(56%) ARKK(55%) IWO(55%) | Factors Impacting TGTX price | TGTX will decline at least -3.435% in a week (0% probabilities). VIXM(-36%) VXX(-33%) UUP(-16%) TLT(-2%) TBT(2%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.435% (StdDev 6.87%) | Hourly BBV | 0 () | Intraday Trend | -3.9% | | | |
|
5 Day Moving Average | $10.14(-2.96%) | 10 Day Moving Average | $9.2(6.96%) | 20 Day Moving Average | $9.62(2.29%) | To recent high | -38.5% | To recent low | 37.8% | Market Cap | $1.246b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |